Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma;Determinación del receptor soluble de la interleucina 2 en el suero de pacientes con linfoma no hodgkiniano

Medicina Clinica

Volumn 111, Issue 5, 1998, Pages 161-167

  Pérez Encinas, Manuel ^a   Bello, José L ^a   Bendaña, Ángeles ^a   Rabuñal, María José ^a   González, Sonia ^a   Abuín, Isabel ^a   Noya, Manuel ^b   Cadarso, Carmen ^b  

^a HOSPITAL GENERAL DE GALICIA   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; SERUM ALBUMIN; TUMOR MARKER; URIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; NONHODGKIN LYMPHOMA; PATHOLOGY; PROGNOSIS; SOLUBILITY; STATISTICAL ANALYSIS; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; C-REACTIVE PROTEIN; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; SERUM ALBUMIN; SOLUBILITY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URIC ACID;

EID: 0032508129     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1.169-1.176.
2. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B. Yarchoan R et al. Soluble interleukin-2 receptors are released by activated lymphocytes in vitro J Immunol 1985; 135: 3.172-3.177.
3. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113: 619-627.
4. Pizzolo G, Chilosi M, Semenzato G. The soluble interleukin-2 receptor in haematoloeical disorders. Br J Haematol 1987; 67: 377-380.
5. Wagner DK, Kiwanuka J, Edwards BK, Rubin LA, Nelson DL. Magrath IT. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 1987: 5: 1.262-1.274.
6. Pui CH, Ip SH. Kung P, Dodge RK, Berard CW. Crist WM et al. High serum interleukin-2 receptor levels are related to advanced disease and poor outcome in childhood non-Hodgkin's lymphoma. Blood 1987; 70: 624-628.
7. Chilosi M, Semenzato G Vinante F, Menestrina F. Piazzola E, Focchiatti V et al. Increased levels of soluble interleukin-2 receptor in non-Hodgkin lymphomas. Relationship with clinical, histologic and phenotypic features Am J Clin Pathol 1989; 92: 186-191.
8. Barak V, Ginzburg M, Kalickman I, Polliack A. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 1992; 7: 431-438.
9. Harrington DS, Patil K, Lai PK, Yasuda NN. Armitage JO, Ip SH et al Soluble interleukin-2 receptors in patients with malignant lymphoma Arch Pathol Lab Med 1988; 112: 597-601.
10. Pavlidis NA, Manoussakis MN, Germanidis GS, Moutsopoulos HM. Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies, Med Pediatr Oncol 1992; 20: 26-31.
11. Motokura T, Kobayashi Y, Fujita A, Nakamura Y. Taniguchi T, Uchimaru K et al. Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma. Leuk Lymphoma 1995; 16: 355-362.
12. Hamon MD, Unal E, McDonald I, Shamim F, Boesen E, Prentice HG. Plasma soluble interleukin-2 receptor levels in patients with malignant lymphoma are correlated with disease activity but not cellular immunosuppression. Leuk Lymphoma 1993; 10: 111-115.
13. Stasi R, Zinzani PL, Galieni P, Michele V, Damasio E. Dispensa E et al. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 770-777.
14. Tangen JM. Abrahamsen AF, Ostenstad B, Bergheim J. Interleukin-2 receptor levels in non-Hodgkin's lymphoma. Acts Oncol 1990; 29: 581-583.
15. Pavlidis AN, Kalef-Ezra J, Bourantas LC, Lambrou A, Mavridrs A. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia Int J Biol Markers 1993; 8: 14-20
16. Real E, Benet I. Marugan I, Pascual A, Lluch A, Arbona C et al. Niveles alevados de receptor soluble de interleucina 2 (sIL-2R) en linfomas; significado clinico y biolȯgico [resumen]. Sangre 1995; 40 (Supl 5): 162.
17. Lennert K, Feller AC. Histopathologie des lymphomes malins non Hodgkinses (2. ed.) Paris: Doin Editeurs, 1991.
18. Pereira A, Cervantes F, Montserrat E, Llebaria C. Rozman C. Non-Hodgkin's lymphoma of unfavourable histology: a multivanate analysis of factors predicting the respones to CHOP. Hematol Oncol 1987; 5: 203-211.
19. Longo DL, DeVita VT, Duffey PL, Wesley MN, lhde EC, Hubbard SM et al. Superiority of Pro-MACE-CytaBOM ever ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial J Clin Oncol 1991; 9: 25-38.
20. Cavalli F. Chemotherapy of non-Hodgkin's lymphomas. Baillieres Clin Haematol 1991; 4: 157-180.
21. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tuviana M, Report of the committee on Hodgkin's disease staging Cancer Res 1971; 31: 1.860-1.861.
22. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cots-wolds Meeting, J Clin Oncol 1989; 7: 1.630-1.635.
23. Orr ST. Aisner J. Performance status assessment among oncology patients. Cancer Treat Rep 1986; 70: 1.423-1.429.
24. The International Non-Hodgkin's Lymphoma Prognostic Factors Proyect. A predictive model for aggressive non-Hodgkin's lymphorna. N Engl J Med 1993; 329: 987-994.
25. Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A et al. for the Groupe d'Etudes des Lymphomes Agressifs. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that colud identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9: 211-219.
26. López-Guillermc A. Montserrat E, Reverter JC, Cervantes F, Escoda L, Tassies D et al. Large-cell lymphoma: a study of prognostic factors and assessment of five recently proposed predictive systems Lenk Lymphoma 1993; 10: 101-109.
27. Swan F Jr, Velásquez WS, Tucker S, Redman JR, Rodriguez MA. McLaughlin P et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactale dehydrogenase levels. J Clin Oncol 1989; 7: 1.518-1.527.
28. Gandanllas MA. Conde E. Mazorra F, Cuadrado MA, Baro J. Garijo J et al. Investigación de fadores pronósticos en linfomas de cėlulas grandes. Med Clin (Barc) 1995; 104: 601-607.
29. Child JA, Spati B, Lllingworth S, Barnard D, Corbett S, Simmons AV et al. Serum beta 2-microglobulin and C-reactive protein in the monitoring of lymphomas; findings in a multicenter study and experience in selected patients Cancer 1980; 45: 318-326.
30. Everitt BS. Statistical inference En: Everitt BS, ed. Statistical methods for medical investigations. Nueva York: Oxford University Press, 1989; 28-39.
31. Dixon DO, McLaughlin P. Hagemeister FB, Freireich EJ. Fuller LM, Cabanillas FF et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 1987; 5: 1.670-1.672.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Ass 1958; 53: 457-481.
33. Peto R, Pike MC, Armitage P. Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35; 1-38.
34. Cox DR. Regression models and life tables (with discussion). J R Stat Sci 1972; 74: 187-220.
35. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission J Clin Oncol 1991; 9: 1.196-1.203.
36. Kalmanti M, Karamolengou K, Dimitriou H, Tosca A. Vlachonikolis I. Peraki M et al. Serum levels of tumor necrosis factor and soluble interleukin-2 receptor as markers of disease activity and prognosis in childhood leukemia and lympioma. Int Hematol 1993; 57: 147-152.
37. Gause A, Roschansky V. Tschiersch A, Smith K, Hasenclever D, Schmits R et al. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. Ann Oncol 1991; 2 (Supl 2): 43-47.
38. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has «high-risk« disease? Blood 1994; 83: 1.165-1.173.